How to buy Heat Biologics stock | $7.91

Heat Biologics, Inc is a biotechnology business based in the US. Heat Biologics shares (HTBX) are listed on the NASDAQ and all prices are listed in US Dollars. Heat Biologics employs 39 staff and has a trailing 12-month revenue of around 0.00.

Heat Biologics share price

Use our graph to track the performance of HTBX stocks over time.

Heat Biologics shares at a glance

• Key figures

Information last updated 2021-05-07.

Latest market close	$7.91
52-week range	$3.71 - $30.10
50-day moving average	$7.15
200-day moving average	$7.47
Wall St. target price	$26.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.65

Buy Heat Biologics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Heat Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Heat Biologics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Heat Biologics price performance over time

Historical closes compared with the close of $7.91 from 2021-02-25

1 week (2021-05-04)	17.36%
1 month (2021-04-09)	6.60%
3 months (2021-02-12)	-30.80%
6 months (2020-11-11)	649.76%

1 year (2020-05-11)	1,312.50%
2 years (2019-05-10)	699.31%
3 years (2018-05-11)	499.24%
5 years (2016-05-11)	1,275.65%

Heat Biologics financials

Revenue TTM	$2.6 million
Gross profit TTM	$-9,990,926
Return on assets TTM	-18.8%
Return on equity TTM	-33.91%
Profit margin	0%
Book value	$5.46
Market capitalisation	$166.9 million

TTM: trailing 12 months

Shorting Heat Biologics shares

There are currently 2.9 million Heat Biologics shares held short by investors – that's known as Heat Biologics's "short interest". This figure is 21.6% up from 2.4 million last month.

There are a few different ways that this level of interest in shorting Heat Biologics shares can be evaluated.

Heat Biologics's "short interest ratio" (SIR)

Heat Biologics's "short interest ratio" (SIR) is the quantity of Heat Biologics shares currently shorted divided by the average quantity of Heat Biologics shares traded daily (recently around 456877.81299525). Heat Biologics's SIR currently stands at 6.31. In other words for every 100,000 Heat Biologics shares traded daily on the market, roughly 6310 shares are currently held short.

However Heat Biologics's short interest can also be evaluated against the total number of Heat Biologics shares, or, against the total number of tradable Heat Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Heat Biologics's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Heat Biologics shares in existence, roughly 110 shares are currently held short) or 0.1186% of the tradable shares (for every 100,000 tradable Heat Biologics shares, roughly 119 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Heat Biologics.

Find out more about how you can short Heat Biologics stock.

Heat Biologics share dividends

We're not expecting Heat Biologics to pay a dividend over the next 12 months.

Have Heat Biologics's shares ever split?

Heat Biologics's shares were split on a 1:7 basis on 10 December 2020. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heat Biologics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Heat Biologics shares which in turn could have impacted Heat Biologics's share price.

Heat Biologics share price volatility

Over the last 12 months, Heat Biologics's shares have ranged in value from as little as $3.7107 up to $30.1. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heat Biologics's is 0.3183. This would suggest that Heat Biologics's shares are less volatile than average (for this exchange).

Heat Biologics overview

Heat Biologics, Inc. , a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130 that is in phase I clinical trial for the treatment of advanced solid tumors. Its preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25; TNFRSF25 modulators for various immunotherapy approaches; and COVID-19 vaccine. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine.

Frequently asked questions

• What percentage of Heat Biologics is owned by insiders or institutions?

  Currently 4.18% of Heat Biologics shares are held by insiders and 11.575% by institutions.

• How many people work for Heat Biologics?

  Latest data suggests 39 work at Heat Biologics.

• When does the fiscal year end for Heat Biologics?

  Heat Biologics's fiscal year ends in December.

• Where is Heat Biologics based?

  Heat Biologics's address is: 627 Davis Drive, Morrisville, NC, United States, 27560

• What is Heat Biologics's ISIN number?

  Heat Biologics's international securities identification number is: US42237K3005

• What is Heat Biologics's CUSIP number?

  Heat Biologics's Committee on Uniform Securities Identification Procedures number is: 42237K102